Cargando…

Replicability of proton MR spectroscopic imaging findings in mild traumatic brain injury: Implications for clinical applications

PURPOSE: Proton magnetic resonance spectroscopy ((1)H MRS) offers biomarkers of metabolic damage after mild traumatic brain injury (mTBI), but a lack of replicability studies hampers clinical translation. In a conceptual replication study design, the results reported in four previous publications we...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Anna M., Gerhalter, Teresa, Dehkharghani, Seena, Peralta, Rosemary, Gajdošík, Mia, Gajdošík, Martin, Tordjman, Mickael, Zabludovsky, Julia, Sheriff, Sulaiman, Ahn, Sinyeob, Babb, James S., Bushnik, Tamara, Zarate, Alejandro, Silver, Jonathan M., Im, Brian S., Wall, Stephen P., Madelin, Guillaume, Kirov, Ivan I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9898311/
https://www.ncbi.nlm.nih.gov/pubmed/36724732
http://dx.doi.org/10.1016/j.nicl.2023.103325
_version_ 1784882399443681280
author Chen, Anna M.
Gerhalter, Teresa
Dehkharghani, Seena
Peralta, Rosemary
Gajdošík, Mia
Gajdošík, Martin
Tordjman, Mickael
Zabludovsky, Julia
Sheriff, Sulaiman
Ahn, Sinyeob
Babb, James S.
Bushnik, Tamara
Zarate, Alejandro
Silver, Jonathan M.
Im, Brian S.
Wall, Stephen P.
Madelin, Guillaume
Kirov, Ivan I.
author_facet Chen, Anna M.
Gerhalter, Teresa
Dehkharghani, Seena
Peralta, Rosemary
Gajdošík, Mia
Gajdošík, Martin
Tordjman, Mickael
Zabludovsky, Julia
Sheriff, Sulaiman
Ahn, Sinyeob
Babb, James S.
Bushnik, Tamara
Zarate, Alejandro
Silver, Jonathan M.
Im, Brian S.
Wall, Stephen P.
Madelin, Guillaume
Kirov, Ivan I.
author_sort Chen, Anna M.
collection PubMed
description PURPOSE: Proton magnetic resonance spectroscopy ((1)H MRS) offers biomarkers of metabolic damage after mild traumatic brain injury (mTBI), but a lack of replicability studies hampers clinical translation. In a conceptual replication study design, the results reported in four previous publications were used as the hypotheses (H1-H7), specifically: abnormalities in patients are diffuse (H1), confined to white matter (WM) (H2), comprise low N-acetyl-aspartate (NAA) levels and normal choline (Cho), creatine (Cr) and myo-inositol (mI) (H3), and correlate with clinical outcome (H4); additionally, a lack of findings in regional subcortical WM (H5) and deep gray matter (GM) structures (H6), except for higher mI in patients’ putamen (H7). METHODS: 26 mTBI patients (20 female, age 36.5 ± 12.5 [mean ± standard deviation] years), within two months from injury and 21 age-, sex-, and education-matched healthy controls were scanned at 3 Tesla with 3D echo-planar spectroscopic imaging. To test H1-H3, global analysis using linear regression was used to obtain metabolite levels of GM and WM in each brain lobe. For H4, patients were stratified into non-recovered and recovered subgroups using the Glasgow Outcome Scale Extended. To test H5-H7, regional analysis using spectral averaging estimated metabolite levels in four GM and six WM structures segmented from T1-weighted MRI. The Mann-Whitney U test and weighted least squares analysis of covariance were used to examine mean group differences in metabolite levels between all patients and all controls (H1-H3, H5-H7), and between recovered and non-recovered patients and their respectively matched controls (H4). Replicability was defined as the support or failure to support the null hypotheses in accordance with the content of H1-H7, and was further evaluated using percent differences, coefficients of variation, and effect size (Cohen’s d). RESULTS: Patients’ occipital lobe WM Cho and Cr levels were 6.0% and 4.6% higher than controls’, respectively (Cho, d = 0.37, p = 0.04; Cr, d = 0.63, p = 0.03). The same findings, i.e., higher patients’ occipital lobe WM Cho and Cr (both p = 0.01), but with larger percent differences (Cho, 8.6%; Cr, 6.3%) and effect sizes (Cho, d = 0.52; Cr, d = 0.88) were found in the comparison of non-recovered patients to their matched controls. For the lobar WM Cho and Cr comparisons without statistical significance (frontal, parietal, temporal), unidirectional effect sizes were observed (Cho, d = 0.07 – 0.37; Cr, d = 0.27 – 0.63). No differences were found in any metabolite in any lobe in the comparison between recovered patients and their matched controls. In the regional analyses, no differences in metabolite levels were found in any GM or WM region, but all WM regions (posterior, frontal, corona radiata, and the genu, body, and splenium of the corpus callosum) exhibited unidirectional effect sizes for Cho and Cr (Cho, d = 0.03 – 0.34; Cr, d = 0.16 – 0.51). CONCLUSIONS: We replicated findings of diffuse WM injury, which correlated with clinical outcome (supporting H1-H2, H4). These findings, however, were among the glial markers Cho and Cr, not the neuronal marker NAA (not supporting H3). No differences were found in regional GM and WM metabolite levels (supporting H5-H6), nor in putaminal mI (not supporting H7). Unidirectional effect sizes of higher patients’ Cho and Cr within all WM analyses suggest widespread injury, and are in line with the conclusion from the previous publications, i.e., that detection of WM injury may be more dependent upon sensitivity of the (1)H MRS technique than on the selection of specific regions. The findings lend further support to the corollary that clinic-ready (1)H MRS biomarkers for mTBI may best be achieved by using high signal-to-noise-ratio single-voxels placed anywhere within WM. The biochemical signature of the injury, however, may differ and therefore absolute levels, rather than ratios may be preferred. Future replication efforts should further test the generalizability of these findings.
format Online
Article
Text
id pubmed-9898311
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-98983112023-02-05 Replicability of proton MR spectroscopic imaging findings in mild traumatic brain injury: Implications for clinical applications Chen, Anna M. Gerhalter, Teresa Dehkharghani, Seena Peralta, Rosemary Gajdošík, Mia Gajdošík, Martin Tordjman, Mickael Zabludovsky, Julia Sheriff, Sulaiman Ahn, Sinyeob Babb, James S. Bushnik, Tamara Zarate, Alejandro Silver, Jonathan M. Im, Brian S. Wall, Stephen P. Madelin, Guillaume Kirov, Ivan I. Neuroimage Clin Regular Article PURPOSE: Proton magnetic resonance spectroscopy ((1)H MRS) offers biomarkers of metabolic damage after mild traumatic brain injury (mTBI), but a lack of replicability studies hampers clinical translation. In a conceptual replication study design, the results reported in four previous publications were used as the hypotheses (H1-H7), specifically: abnormalities in patients are diffuse (H1), confined to white matter (WM) (H2), comprise low N-acetyl-aspartate (NAA) levels and normal choline (Cho), creatine (Cr) and myo-inositol (mI) (H3), and correlate with clinical outcome (H4); additionally, a lack of findings in regional subcortical WM (H5) and deep gray matter (GM) structures (H6), except for higher mI in patients’ putamen (H7). METHODS: 26 mTBI patients (20 female, age 36.5 ± 12.5 [mean ± standard deviation] years), within two months from injury and 21 age-, sex-, and education-matched healthy controls were scanned at 3 Tesla with 3D echo-planar spectroscopic imaging. To test H1-H3, global analysis using linear regression was used to obtain metabolite levels of GM and WM in each brain lobe. For H4, patients were stratified into non-recovered and recovered subgroups using the Glasgow Outcome Scale Extended. To test H5-H7, regional analysis using spectral averaging estimated metabolite levels in four GM and six WM structures segmented from T1-weighted MRI. The Mann-Whitney U test and weighted least squares analysis of covariance were used to examine mean group differences in metabolite levels between all patients and all controls (H1-H3, H5-H7), and between recovered and non-recovered patients and their respectively matched controls (H4). Replicability was defined as the support or failure to support the null hypotheses in accordance with the content of H1-H7, and was further evaluated using percent differences, coefficients of variation, and effect size (Cohen’s d). RESULTS: Patients’ occipital lobe WM Cho and Cr levels were 6.0% and 4.6% higher than controls’, respectively (Cho, d = 0.37, p = 0.04; Cr, d = 0.63, p = 0.03). The same findings, i.e., higher patients’ occipital lobe WM Cho and Cr (both p = 0.01), but with larger percent differences (Cho, 8.6%; Cr, 6.3%) and effect sizes (Cho, d = 0.52; Cr, d = 0.88) were found in the comparison of non-recovered patients to their matched controls. For the lobar WM Cho and Cr comparisons without statistical significance (frontal, parietal, temporal), unidirectional effect sizes were observed (Cho, d = 0.07 – 0.37; Cr, d = 0.27 – 0.63). No differences were found in any metabolite in any lobe in the comparison between recovered patients and their matched controls. In the regional analyses, no differences in metabolite levels were found in any GM or WM region, but all WM regions (posterior, frontal, corona radiata, and the genu, body, and splenium of the corpus callosum) exhibited unidirectional effect sizes for Cho and Cr (Cho, d = 0.03 – 0.34; Cr, d = 0.16 – 0.51). CONCLUSIONS: We replicated findings of diffuse WM injury, which correlated with clinical outcome (supporting H1-H2, H4). These findings, however, were among the glial markers Cho and Cr, not the neuronal marker NAA (not supporting H3). No differences were found in regional GM and WM metabolite levels (supporting H5-H6), nor in putaminal mI (not supporting H7). Unidirectional effect sizes of higher patients’ Cho and Cr within all WM analyses suggest widespread injury, and are in line with the conclusion from the previous publications, i.e., that detection of WM injury may be more dependent upon sensitivity of the (1)H MRS technique than on the selection of specific regions. The findings lend further support to the corollary that clinic-ready (1)H MRS biomarkers for mTBI may best be achieved by using high signal-to-noise-ratio single-voxels placed anywhere within WM. The biochemical signature of the injury, however, may differ and therefore absolute levels, rather than ratios may be preferred. Future replication efforts should further test the generalizability of these findings. Elsevier 2023-01-19 /pmc/articles/PMC9898311/ /pubmed/36724732 http://dx.doi.org/10.1016/j.nicl.2023.103325 Text en © 2023 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Regular Article
Chen, Anna M.
Gerhalter, Teresa
Dehkharghani, Seena
Peralta, Rosemary
Gajdošík, Mia
Gajdošík, Martin
Tordjman, Mickael
Zabludovsky, Julia
Sheriff, Sulaiman
Ahn, Sinyeob
Babb, James S.
Bushnik, Tamara
Zarate, Alejandro
Silver, Jonathan M.
Im, Brian S.
Wall, Stephen P.
Madelin, Guillaume
Kirov, Ivan I.
Replicability of proton MR spectroscopic imaging findings in mild traumatic brain injury: Implications for clinical applications
title Replicability of proton MR spectroscopic imaging findings in mild traumatic brain injury: Implications for clinical applications
title_full Replicability of proton MR spectroscopic imaging findings in mild traumatic brain injury: Implications for clinical applications
title_fullStr Replicability of proton MR spectroscopic imaging findings in mild traumatic brain injury: Implications for clinical applications
title_full_unstemmed Replicability of proton MR spectroscopic imaging findings in mild traumatic brain injury: Implications for clinical applications
title_short Replicability of proton MR spectroscopic imaging findings in mild traumatic brain injury: Implications for clinical applications
title_sort replicability of proton mr spectroscopic imaging findings in mild traumatic brain injury: implications for clinical applications
topic Regular Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9898311/
https://www.ncbi.nlm.nih.gov/pubmed/36724732
http://dx.doi.org/10.1016/j.nicl.2023.103325
work_keys_str_mv AT chenannam replicabilityofprotonmrspectroscopicimagingfindingsinmildtraumaticbraininjuryimplicationsforclinicalapplications
AT gerhalterteresa replicabilityofprotonmrspectroscopicimagingfindingsinmildtraumaticbraininjuryimplicationsforclinicalapplications
AT dehkharghaniseena replicabilityofprotonmrspectroscopicimagingfindingsinmildtraumaticbraininjuryimplicationsforclinicalapplications
AT peraltarosemary replicabilityofprotonmrspectroscopicimagingfindingsinmildtraumaticbraininjuryimplicationsforclinicalapplications
AT gajdosikmia replicabilityofprotonmrspectroscopicimagingfindingsinmildtraumaticbraininjuryimplicationsforclinicalapplications
AT gajdosikmartin replicabilityofprotonmrspectroscopicimagingfindingsinmildtraumaticbraininjuryimplicationsforclinicalapplications
AT tordjmanmickael replicabilityofprotonmrspectroscopicimagingfindingsinmildtraumaticbraininjuryimplicationsforclinicalapplications
AT zabludovskyjulia replicabilityofprotonmrspectroscopicimagingfindingsinmildtraumaticbraininjuryimplicationsforclinicalapplications
AT sheriffsulaiman replicabilityofprotonmrspectroscopicimagingfindingsinmildtraumaticbraininjuryimplicationsforclinicalapplications
AT ahnsinyeob replicabilityofprotonmrspectroscopicimagingfindingsinmildtraumaticbraininjuryimplicationsforclinicalapplications
AT babbjamess replicabilityofprotonmrspectroscopicimagingfindingsinmildtraumaticbraininjuryimplicationsforclinicalapplications
AT bushniktamara replicabilityofprotonmrspectroscopicimagingfindingsinmildtraumaticbraininjuryimplicationsforclinicalapplications
AT zaratealejandro replicabilityofprotonmrspectroscopicimagingfindingsinmildtraumaticbraininjuryimplicationsforclinicalapplications
AT silverjonathanm replicabilityofprotonmrspectroscopicimagingfindingsinmildtraumaticbraininjuryimplicationsforclinicalapplications
AT imbrians replicabilityofprotonmrspectroscopicimagingfindingsinmildtraumaticbraininjuryimplicationsforclinicalapplications
AT wallstephenp replicabilityofprotonmrspectroscopicimagingfindingsinmildtraumaticbraininjuryimplicationsforclinicalapplications
AT madelinguillaume replicabilityofprotonmrspectroscopicimagingfindingsinmildtraumaticbraininjuryimplicationsforclinicalapplications
AT kirovivani replicabilityofprotonmrspectroscopicimagingfindingsinmildtraumaticbraininjuryimplicationsforclinicalapplications